In human NSCLC cells, oncogenic activation of KRAS transcriptionally promoted NRF2 expression through the 12-O-tetradecanoylphorbol-13-acetate (TPA)-response element, demonstrating the involvement of the KRAS-NRF2 axis in cisplatin resistance [52]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.